Alpha Windward’s Acadia Pharmaceuticals ACAD Stock Holding History

Alpha Windward’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-182	Closed	-$8K	–	7
2020 Q3	$8K	Sell	182 -100	-35%	-$4.32K	0.01%	370
2020 Q2	$14K	Sell	282 -156	-36%	-$7.49K	0.01%	348
2020 Q1	$19K	Hold	438	–	–	0.02%	318
2019 Q4	$19K	Buy	+438	New	+$19.1K	0.01%	341

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alpha Windward's ACAD Position: Q4 2020 in Review

Alpha Windward sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 182 shares — an estimated $8K sold.

Alpha Windward first reported a position in ACAD in Q4 2019 and held it in 4 quarters. The position peaked at $19K in Q1 2020. 307 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

Alpha Windward reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Alpha Windward sold 182 Acadia Pharmaceuticals shares in Q4 2020, an estimated $8K.
Alpha Windward first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Alpha Windward's Acadia Pharmaceuticals position peaked at $19K in Q1 2020.
307 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on Alpha Windward's 13F filing for Q4 2020.